Korean Practice Patterns for Screening PCA(Prostate Cancer) (RESPECT)

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01371513
First received: May 12, 2011
Last updated: November 3, 2011
Last verified: October 2011

May 12, 2011
November 3, 2011
May 2010
June 2011   (final data collection date for primary outcome measure)
Number of subjects with prostate biopsy [ Time Frame: 1year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01371513 on ClinicalTrials.gov Archive Site
Number of subjects with prostate cancer [ Time Frame: 1year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Korean Practice Patterns for Screening PCA(Prostate Cancer)
Korean's Practice Patterns for Screening PCA(Prostate Cancer) According to PSA(Prostate-specific Antigen) Level

This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.

This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Subjects with PSA more than 2.5ng/ml in 2008 from urology department of clinic and general hospital

  • Neoplasms, Prostate
  • Prostate Cancer
  • Benign Prostatic Hyperplasia
Other: continuous screening
practice patterns for screening prostate cancer
PSA level
more than 2.5ng/ml
Intervention: Other: continuous screening
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1
June 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male with PSA more than 2.5ng/ml from 1 Jan 2008 to 31 Dec 2008

Exclusion Criteria:

  • Age less than 40 at PSA screening
  • History of drug use which can affect level of PSA within 6months before PSA screening
  • Subject who participate any other clinical trial
Male
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01371513
113951
No
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP